Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is expected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The firm had revenue of $0.17 million for the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Stock Down 3.6 %

Quince Therapeutics stock opened at $1.35 on Monday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a fifty day simple moving average of $1.47 and a 200 day simple moving average of $1.46. The company has a market cap of $59.40 million, a P/E ratio of -1.09 and a beta of 0.71.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Oppenheimer started coverage on Quince Therapeutics in a research report on Monday, March 24th. They issued an “outperform” rating and a $10.00 target price on the stock. Brookline Capital Management began coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. Finally, D. Boral Capital dropped their price objective on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Quince Therapeutics has an average rating of “Buy” and an average target price of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.